ERBB3 Antibody (ARP30252_P050)
- Known as:
- ERBB3 Antibody (ARP30252_P050)
- Catalog number:
- arp30252_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ERBB3 Antibody (ARP30252_P050)
Related genes to: ERBB3 Antibody (ARP30252_P050)
- Gene:
- ERBB3 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 3
- Previous symbol:
- LCCS2
- Synonyms:
- HER3
- Chromosome:
- 12q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-07-15
- Date modifiied:
- 2019-04-23
Related products to: ERBB3 Antibody (ARP30252_P050)
Related articles to: ERBB3 Antibody (ARP30252_P050)
- - Source: PubMed
Publication date: 2026/09/10
De Bacco FrancescaOrzan FrancescaErriquez JessicaCasanova ElenaBarault LudovicAlbano RaffaellaD'Ambrosio AntonioBigatto ViolaReato GigliolaPatanè MonicaPollo BiancaKuesters GeoffreyDell'Aglio CarmineCasorzo LauraPellegatta SerenaFinocchiaro GaetanoComoglio Paolo MBoccaccio Carla - Autologous CAR-T therapy has achieved notable success in B-cell malignancies, yet its broader application is constrained by high costs, protracted manufacturing timelines, and severe toxicities, including cytokine release syndrome (CRS) and graft-versus-host disease (GVHD). Natural killer (NK) cells offer a compelling off-the-shelf alternative, owing to their major histocompatibility complex-independent cytotoxicity and negligible GVHD risk. Among allogeneic NK sources, umbilical cord blood (UCB)-derived CAR-NK cells are distinguished by a CD56brightCD16-/dim phenotype, extended telomeres, and a transcriptional profile that facilitates >1,000-fold ex vivo expansion. These properties have supported extensive preclinical evaluation and early clinical translation. Preclinical studies have documented antitumor activity against CD19, CD123, PD-L1, ErbB3, and mesothelin, without evidence of CRS. In a landmark phase I/II trial (NCT03056339), 7 of 11 patients (64%) with relapsed or refractory CD19+ B-cell malignancies achieved complete remission, with no observed GVHD or neurotoxicity. However, relapses occurring within 2 to 3 months correlated with loss of detectable CAR-NK cells, highlighting limited in vivo persistence as a principal barrier to durable response. - Source: PubMed
Publication date: 2026/09/03
Lu KunCai Mei-LianLi JingLi Tao - Gastric cancer is a major global health issue, especially in advanced stages with metastasis. However, anti-angiogenic treatments such as ramucirumab target vascular endothelial growth factor, yet the exact mechanisms behind hematogenous metastasis remain unclear. This study analyzed RNA sequencing data from TCGA to identify angiogenesis-related genes in metastatic gastric cancer. - Source: PubMed
Publication date: 2026/08/31
Yoo JaeunKim Hyun MyongJeong KyoungyunYoo Yie-RiShin Ji-YeonLee SeunghoLee SeungbokLee Hye SeungPark Kyoung UnKong Seong-HoPark Do JoongLee Hyuk-JoonYang Han-Kwang - Clear cell renal cell carcinoma (ccRCC) is the predominant subtype of renal cancer with poor prognosis at advanced stages. The ErbB receptor family, including HER2, EGFR, and ErbB3, is implicated in tumor progression through membrane signaling and nuclear functions, but their roles in ccRCC remain incompletely understood. - Source: PubMed
Cortés María AliciaMarín Héctor MarceloCordo-Ruso RosaliaRott LuciaGiusiano Gustavo EmilioMerino Luis Antonio - Hyperuricemia (HUA) and acute gouty arthritis (AGA) represent distinct pathological stages of gout, with the intestine playing a critical role in uric acid (UA) excretion. By establishing HUA and AGA mouse models, we observed both induced renal and intestinal pathology, elevated inflammatory factors, reduced expression of barrier proteins (Occludin, Claudin-1, and Zonula occludens-1 [ZO-1]), increased permeability markers (DAO and D-LA), upregulation of GLUT9, downregulation of ABCG2, and more severe pathology in AGA. 16S rRNA sequencing revealed alterations in gut microbial composition, with 11 bacterial genera overlapping between the 2, including , , , etc. Application of gut microbiota from two models to intestinal epithelial cells (IECs) confirmed that these microbiota exacerbated damage in HUA/NCM460 and AGA/NCM460 cells. RNA sequencing identified the ErbB3/PI3K/AKT pathway as significantly activated in HUA, and the ADRB2/cAMP/PKA/CREB pathway in AGA, which were further validated . This study identifies specific gut microbiota in HUA/AGA and elucidates core pathways involved in pathogenesis, providing new insights into gut-targeted management strategies. - Source: PubMed
Publication date: 2026/08/24
Wang MeilingYang RuifangAn HonglinChen BingyanChen QianglongChen ZejunLi MengyuanYang FanXiao YanChen PengGuo JiemeiSu YouxinHuang Bin